Compare Cadila Healthcare with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs WOCKHARDT - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE WOCKHARDT CADILA HEALTHCARE/
WOCKHARDT
 
P/E (TTM) x 35.1 -104.0 - View Chart
P/BV x 6.2 2.3 267.1% View Chart
Dividend Yield % 0.6 0.0 33,508.0%  

Financials

 CADILA HEALTHCARE   WOCKHARDT
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
WOCKHARDT
Mar-18
CADILA HEALTHCARE/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs3521,012 34.8%   
Low Rs207532 38.9%   
Sales per share (Unadj.) Rs139.2355.9 39.1%  
Earnings per share (Unadj.) Rs11.8-60.3 -19.5%  
Cash flow per share (Unadj.) Rs18.6-46.8 -39.7%  
Dividends per share (Unadj.) Rs3.500.01 35,000.0%  
Dividend yield (eoy) %1.30 96,675.9%  
Book value per share (Unadj.) Rs101.4257.8 39.3%  
Shares outstanding (eoy) m1,023.74110.63 925.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.02.2 92.5%   
Avg P/E ratio x23.7-12.8 -185.5%  
P/CF ratio (eoy) x15.0-16.5 -91.2%  
Price / Book Value ratio x2.83.0 92.1%  
Dividend payout %29.80 -179,325.6%   
Avg Mkt Cap Rs m286,03385,379 335.0%   
No. of employees `00013.46.3 214.3%   
Total wages/salary Rs m24,1459,371 257.7%   
Avg. sales/employee Rs Th10,632.76,295.0 168.9%   
Avg. wages/employee Rs Th1,801.21,498.3 120.2%   
Avg. net profit/employee Rs Th898.5-1,066.3 -84.3%   
INCOME DATA
Net Sales Rs m142,53139,369 362.0%  
Other income Rs m1,1391,202 94.7%   
Total revenues Rs m143,67040,571 354.1%   
Gross profit Rs m24,19818 132,229.5%  
Depreciation Rs m6,9651,495 465.8%   
Interest Rs m3,4182,555 133.8%   
Profit before tax Rs m14,954-2,830 -528.5%   
Minority Interest Rs m2880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m3,198257 1,244.4%   
Profit after tax Rs m12,044-6,669 -180.6%  
Gross profit margin %17.00 36,523.6%  
Effective tax rate %21.4-9.1 -235.5%   
Net profit margin %8.5-16.9 -49.9%  
BALANCE SHEET DATA
Current assets Rs m87,15433,796 257.9%   
Current liabilities Rs m82,69426,917 307.2%   
Net working cap to sales %3.117.5 17.9%  
Current ratio x1.11.3 83.9%  
Inventory Days Days7179 90.0%  
Debtors Days Days9489 105.1%  
Net fixed assets Rs m133,23639,664 335.9%   
Share capital Rs m1,024553 185.1%   
"Free" reserves Rs m102,73327,968 367.3%   
Net worth Rs m103,75728,522 363.8%   
Long term debt Rs m32,14621,731 147.9%   
Total assets Rs m236,86681,620 290.2%  
Interest coverage x5.4-0.1 -4,999.2%   
Debt to equity ratio x0.30.8 40.7%  
Sales to assets ratio x0.60.5 124.8%   
Return on assets %6.5-5.0 -129.5%  
Return on equity %11.6-23.4 -49.6%  
Return on capital %13.7-7.7 -178.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52,7529,807 537.9%   
Fx outflow Rs m14,5041,789 810.9%   
Net fx Rs m38,2488,019 477.0%   
CASH FLOW
From Operations Rs m25,054684 3,660.7%  
From Investments Rs m-10,1236,302 -160.6%  
From Financial Activity Rs m-10,942-7,695 142.2%  
Net Cashflow Rs m3,989-664 -600.8%  

Share Holding

Indian Promoters % 74.8 74.5 100.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 2.3 360.9%  
FIIs % 5.9 7.7 76.6%  
ADR/GDR % 0.0 0.1 -  
Free float % 11.0 15.4 71.4%  
Shareholders   44,069 67,757 65.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   SUN PHARMA  PROCTER & GAMBLE HEALTH  SANOFI INDIA  UNICHEM LAB  ORCHID PHARMA  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 296 Points Higher; Coal India, UPL & Hindalco Surge Over 6%(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

GLENMARK PHARMA Share Price Up by 6%; BSE HEALTHCARE Index Up 2.0% (Market Updates)

May 10, 2021 | Updated on May 10, 2021

GLENMARK PHARMA share price is trading up by 6% and its current market price is Rs 631. The BSE HEALTHCARE is up by 2.0%. The top gainers in the BSE HEALTHCARE Index are GLENMARK PHARMA (up 6.3%) and ALKEM LABORATORIES (up 5.3%). The top losers are GSK PHARMA and APOLLO HOSPITALS .

AUROBINDO PHARMA at 52 Week High; BSE 500 Index Up 1.0% (Market Updates)

May 10, 2021 | Updated on May 10, 2021

AUROBINDO PHARMA share price has hit a 52-week high. It is presently trading at Rs 1,047. BSE 500 Index is up by 0.7% at 20,165. Within the BSE 500, AUROBINDO PHARMA (up 2.4%) and GMDC (up 16.0%) are among the top gainers, while top losers are CHOLAMANDALAM INVEST and COFORGE.

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


May 10, 2021 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS